Novartis AG Revenue 2006-2018 | NVS

Novartis AG annual/quarterly revenue history and growth rate from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Novartis AG revenue for the quarter ending June 30, 2018 was $13.452B, a 7.67% increase year-over-year.
  • Novartis AG revenue for the twelve months ending June 30, 2018 was $52.237B, a 6.12% increase year-over-year.
  • Novartis AG annual revenue for 2017 was $50.135B, a 1.41% increase from 2016.
  • Novartis AG annual revenue for 2016 was $49.436B, a 1.89% decline from 2015.
  • Novartis AG annual revenue for 2015 was $50.387B, a 6.05% decline from 2014.
Novartis AG Annual Revenue
(Millions of US $)
2017 $50,135
2016 $49,436
2015 $50,387
2014 $53,634
2013 $52,716
2012 $51,971
2011 $59,375
2010 $51,561
2009 $45,103
2008 $42,584
2007 $38,947
2006 $35,105
2005 $29,753
Novartis AG Quarterly Revenue
(Millions of US $)
Q2 2018 $13,452
Q1 2018 $12,929
Q4 2017 $13,164
Q3 2017 $12,692
Q2 2017 $12,494
Q1 2017 $11,785
Q4 2016 $12,606
Q3 2016 $12,341
Q2 2016 $12,679
Q1 2016 $11,810
Q4 2015 $12,804
Q3 2015 $12,485
Q2 2015 $12,896
Q1 2015 $12,202
Q4 2014 $13,354
Q3 2014 $13,300
Q2 2014 $13,949
Q1 2014 $13,031
Q4 2013 $12,324
Q3 2013 $12,906
Q2 2013 $13,280
Q1 2013 $14,206
Q4 2012 $9,478
Q3 2012 $14,039
Q2 2012 $14,541
Q1 2012 $13,913
Q4 2011 $14,996
Q3 2011 $15,034
Q2 2011 $15,123
Q1 2011 $14,222
Q4 2010 $14,464
Q3 2010 $12,820
Q2 2010 $11,921
Q1 2010 $12,356
Q4 2009 $13,145
Q3 2009 $11,290
Q2 2009 $10,742
Q1 2009 $9,926
Q4 2008 $10,348
Q3 2008 $11,030
Q2 2008 $10,990
Q1 2008 $10,216
Q4 2007 $10,171
Q3 2007 $9,818
Q2 2007 $9,584
Q1 2007 $9,374
Q4 2006 $9,260
Q3 2006 $9,024
Q2 2006 $8,671
Q1 2006 $8,150
Q4 2005 $5,980
Q3 2005 $8,489
Q2 2005 $7,870
Q1 2005 $7,414
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $198.652B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $366.377B 17.18
Pfizer (PFE) United States $261.509B 15.31
Merck (MRK) United States $192.023B 16.96
AbbVie (ABBV) United States $139.177B 13.60
Eli Lilly (LLY) United States $119.245B 22.07
Sanofi (SNY) France $111.234B 14.08
Novo Nordisk (NVO) Denmark $106.025B 16.95
AstraZeneca (AZN) United Kingdom $98.986B 10.89
GlaxoSmithKline (GSK) United Kingdom $98.701B 13.18
Bristol-Myers Squibb (BMY) United States $94.525B 17.11